Replimune Group Inc.

About Replimune Group Inc.

Replimune is a clinical-stage biotech company focused on revolutionizing cancer treatment through a novel class of oncolytic immunotherapies designed to activate a powerful and durable systemic anti-tumor immune response. Their mission is to make cancer a curable disease by comprehensively activating a tumor-specific immune response across a broad range of cancer types.

Products & Services

Oncolytic Immunotherapies:A novel class of therapies intended to kill tumors locally, alter the tumor microenvironment, and ignite a powerful anti-tumor immune response.

Specialties

Oncolytic Immunotherapies Cancer Treatment Tumor-Specific Immune Response

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Public Offering T: - FT: Public Offering	A: 140000000 MR: - FA: approximately $140 million FAN: 140000000	D: 2024-11-25 FD: 2024-11-25	1 investors
2	RT: Public Offering T: - FT: Public Offering	A: 125000000 MR: - FA: $125 million FAN: 125000000	D: 2024-11-25 FD: 2024-11-25	1 investors
3	RT: PIPE T: - FT: PIPE	A: 100000000 MR: - FA: approximately $100 million FAN: 100000000	D: 2024-06-13 FD: 2024-06-13	5 investors

Public Offering Latest

2024-11-25

$140.0M

1 investor (Pro only)

Public Offering 2024-11-25

$125.0M

PIPE 2024-06-13

$100.0M

View 2 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

S

Sushil Patel

Chief Executive Officer

K

Kostas Xynos

Chief Medical Officer

C

Chris Sarchi

Chief Commercial Officer

E

Emily Hill

Chief Financial Officer

P

Paul Bullock

Chief Manufacturing Officer

C

Camilo Garcia

Chief HR Officer

View 17 more team members with Pro

Unlock Full Team Directory

Recent News